Wedbush Securities Inc. Lowers Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Wedbush Securities Inc. trimmed its holdings in Dynavax Technologies Co. (NASDAQ:DVAX) by 21.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 14,530 shares of the biopharmaceutical company’s stock after selling 4,050 shares during the quarter. Wedbush Securities Inc.’s holdings in Dynavax Technologies were worth $163,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of DVAX. Natixis Advisors L.P. boosted its stake in shares of Dynavax Technologies by 10.5% during the 4th quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 1,804 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Dynavax Technologies by 23.6% during the 4th quarter. BNP Paribas Financial Markets now owns 413,409 shares of the biopharmaceutical company’s stock worth $5,779,000 after acquiring an additional 78,824 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Dynavax Technologies by 7.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,032,139 shares of the biopharmaceutical company’s stock worth $56,372,000 after acquiring an additional 293,337 shares in the last quarter. UBS Group AG boosted its stake in shares of Dynavax Technologies by 427.2% during the 4th quarter. UBS Group AG now owns 647,911 shares of the biopharmaceutical company’s stock worth $9,058,000 after acquiring an additional 525,012 shares in the last quarter. Finally, Trexquant Investment LP boosted its stake in shares of Dynavax Technologies by 51.3% during the 4th quarter. Trexquant Investment LP now owns 263,912 shares of the biopharmaceutical company’s stock worth $3,689,000 after acquiring an additional 89,521 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DVAX has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating and set a $29.00 target price on shares of Dynavax Technologies in a research note on Wednesday, August 7th. StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Finally, The Goldman Sachs Group reduced their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $23.67.

Dynavax Technologies Stock Up 1.8 %

DVAX stock opened at $11.17 on Monday. The company has a market cap of $1.46 billion, a price-to-earnings ratio of 186.17 and a beta of 1.37. The company has a current ratio of 14.18, a quick ratio of 13.18 and a debt-to-equity ratio of 0.35. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $15.15. The firm has a 50-day moving average of $11.00 and a two-hundred day moving average of $11.52.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. The company had revenue of $73.80 million during the quarter, compared to the consensus estimate of $76.92 million. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. During the same quarter in the prior year, the firm earned $0.03 EPS. As a group, analysts forecast that Dynavax Technologies Co. will post 0.16 earnings per share for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.